Research Signal – Source date 2023-05-01
The idea behind this clinical-trial registry entry is simple to state but easy to overread. Investigators planned a small, open-label pilot for older people with treatment-resistant depression or schizophrenia, asking whether dasatinib plus quercetin could be studied as an intervention for aging-related biology alongside psychiatric care. The record describes up to 40 participants and names safety and feasibility as central aims. It is a plan for an investigation, not evidence that the combination slowed aging, cleared senescent cells, improved symptoms, or helped anyone function better.
Why aging enters the psychiatric question
Schizophrenia and treatment-resistant depression are the two specified conditions. The investigators describe them as associated with accelerated aging, so the study does not treat age-related biology as a separate background issue. It asks whether physiological aging can be examined alongside neuropsychological performance, daily function and symptoms in older people with either of these conditions.
Dasatinib and quercetin were chosen because the registry describes both as having senolytic properties. Senolytics are agents intended to target senescent cells, cells associated with a state of cellular aging. That is the study’s rationale for testing the pair; it is not a finding that the drugs removed such cells in these participants. The trial’s value would come from seeing whether its planned measurements move together in a safe and interpretable way, not from the label alone.
What the measurements could reveal
One reason this design matters is that aging can mean several different things. A change in SASP, or senescence-associated secretory phenotype, would address secretions associated with senescent cells. It would be a biological signal, not a direct measure of whether a person thinks more clearly.
Neuropsychological assessments address thinking and memory. Functional-status measures ask about everyday capability. Clinical assessments of depression or schizophrenia symptoms address psychiatric experience and illness burden. Brain markers of aging add another biological perspective. The registry separates acute and longer-term changes, which matters because a short-lived response and a durable shift would carry different implications.
The schedule reflects those different questions. The plan calls for MRI at baseline and around week 10, blood draws at baseline, weeks 1 through 4, week 10 and the endpoint, plus questionnaires and other assessments at baseline, week 10 and the endpoint. A marker could change without daily life changing; symptoms could shift without proving that aging-related biology changed. Keeping those outcomes separate is essential to interpreting what the pilot might actually show.
The intervention includes more than tablets
Participants are intended to self-administer eight total doses: two consecutive days of dasatinib 100 mg plus quercetin 1,250 mg in each of four weekly cycles, with five days off in each week. The planned involvement lasts about a year, even though the medication schedule is concentrated in the first four weeks. These details describe the proposed protocol, not an instruction for personal treatment.
The study also combines the medication intervention with lifestyle-based risk-factor management. The research team is expected to provide education focused on strength, balance and nutrition, stay in close contact, encourage participation and help address barriers. Those supports are part of the experience being studied. If later measures changed, the description alone would not separate the contribution of the drug combination from the contribution of education, encouragement or changes in activity and nutrition.
The small scale and open-label design place the work in an exploratory category. Because it is open-label, the people receiving the intervention and the research team know what is being given. The stated pilot purpose is to examine safety and feasibility; with up to 40 participants, the design is not a strong basis for broad conclusions across psychiatric diagnoses. The evidence available here does not establish how many people enrolled, received the intervention or completed follow-up, or verify recruitment status, study start, completion or results-posting dates. That evidence also leaves comparator arrangements, allocation procedures and particular measurement instruments unverified. Those limits matter when judging what the planned design could eventually show.
What this could change
The prospective benefit is specific: older patients might eventually receive psychiatric care that also helps preserve thinking and everyday function by addressing aging-related biology. Reaching that point would require acceptable safety and reproducible, clinically meaningful benefits that can be attributed to the intervention rather than to ordinary change or the lifestyle-support component.
This pilot asks whether that larger clinical possibility is worth pursuing and how it should be measured. Its historical contribution is to bring biological aging, psychiatric symptoms and everyday function into one planned investigation. For now, the registry captures a bounded research question: whether a proposed aging-related intervention can be safe, workable and relevant to the lives of older people with these conditions.
Key Sources
- Primary source: Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
Government or Regulator · Clinical Trial · 2023-05-01
Keep exploring